Corey J. Langer, MD
Director of Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, PhiladelphiaAuthored Items
February 2011 Vol 2, No 1
Maintenance therapy has begun to emerge as a treatment standard for patients with non–small cell lung cancer (NSCLC) whose disease has not progressed after 4 to 6 cycles of frontline chemotherapy.
Last modified: April 20, 2021